Fanconi Anemia Complementation Group N Protein
"Fanconi Anemia Complementation Group N Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A Fanconi anemia complementation group protein that contains an N-terminal DNA-binding region and seven, C-terminal, WD REPEATS. It is an essential factor in HOMOLOGOUS RECOMBINATION DNA REPAIR through its interactions with BRCA2 PROTEIN; RAD51 RECOMBINASE; and BRCA1 PROTEIN. It functions as a molecular scaffold to localize and stabilize these proteins at homologous recombination sites. Mutations in the PALB2 gene are associated with FANCONI ANEMIA complementation group N; type 3 PANCREATIC NEOPLASMS; and susceptibility to BREAST CANCER.
| Descriptor ID |
D000076164
|
| MeSH Number(s) |
D12.776.313.953 D12.776.624.776.051 D12.776.660.323
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Fanconi Anemia Complementation Group N Protein".
Below are MeSH descriptors whose meaning is more specific than "Fanconi Anemia Complementation Group N Protein".
This graph shows the total number of publications written about "Fanconi Anemia Complementation Group N Protein" by people in this website by year, and whether "Fanconi Anemia Complementation Group N Protein" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Fanconi Anemia Complementation Group N Protein" by people in Profiles.
-
Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program. Clin Cancer Res. 2022 06 01; 28(11):2349-2360.
-
von Ebner's glands intercalated duct adenocarcinoma with PALB2 gene mutation. Ann Diagn Pathol. 2020 Dec; 49:151637.
-
Population-based targeted sequencing of 54 candidate genes identifies PALB2 as a susceptibility gene for high-grade serous ovarian cancer. J Med Genet. 2021 05; 58(5):305-313.
-
Germline DNA Sequencing Reveals Novel Mutations Predictive of Overall Survival in a Cohort of Patients with Pancreatic Cancer. Clin Cancer Res. 2020 03 15; 26(6):1385-1394.
-
Screening of over 1000 Indian patients with breast and/or ovarian cancer with a multi-gene panel: prevalence of BRCA1/2 and non-BRCA mutations. Breast Cancer Res Treat. 2018 Jul; 170(1):189-196.
-
PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. J Med Genet. 2016 12; 53(12):800-811.
-
Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673. Pediatr Blood Cancer. 2015 Jan; 62(1):91-8.
-
Plasticity of BRCA2 function in homologous recombination: genetic interactions of the PALB2 and DNA binding domains. PLoS Genet. 2011 Dec; 7(12):e1002409.
-
Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol Cancer Ther. 2011 Jan; 10(1):3-8.
-
Enhancement of RAD51 recombinase activity by the tumor suppressor PALB2. Nat Struct Mol Biol. 2010 Oct; 17(10):1255-9.